- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01150318
Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients (SAPIRA)
Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Papillary cancer may affect patients of any age,with a good prognosis. Most of young patients may hence procreate as often as the general population.
131iodine is an essential tool during treatment of thyroid cancer, concerning ablation of the orthotopic thyroid remnant and/or distant metastasis. According literature data, 131iodine given patients may experience exocrine testicular dysfunction with transient azoospermia, as a significant growing number of DNA damage may concern the patient or his offspring. No higher malformation risk has been described in children fathered by patients who has received 131iodine for thyroid cancer. But animal studies showed a genomic instability leading to a major cancer risk in the offspring of male mice receiving isotopic radiotherapy. The deduced hypothesis is that a genetic toxicity of those radiation exists on the germ cells, and most of all that those acquired mutations may be transmitted to the next generation, majoring a risk of somatic mutation accumulation. So is described TCHERNOBYL exposed patients and their children. Unfortunately, little is known on trans-generational genomic instability.
The primary outcome will be to study a genomic instability within the germinal line, based on a significant mutation rate analysis in their minisatellite regions after 100 mCi 131 iodine irradiation compared to the baseline spermogram of each patient, thus being his own control case in a cross-over study. Literature reports a risk ratio rising from 1,4 to 1,6 for a comparable exposition dose. Under a 2,5 % spontaneous mutation rate hypothesis and for 1000 minisatellites studied per subject, with the mutation rate rising to 50% (RR=1,5), as the inter-individual variability is expected to be high : the inclusion of 50 patients treated by surgery prior to131iodine would result in statistically significant results.
Secondary outcomes will be to look for deleterious endpoints on spermatogenesis, such as : apparition of a low number of spermatozoids, a low vitality, a low mobility, elevated apoptosis and aneuploidy rate found in sperm of treated subjects vs before iodine treatment. Therefore, the kinetics of spermogram parameters alteration will be available. Testosterone/LH ratio will be assessed before and after 131iodine. Direct measure of testis irradiation obtained by a scrotal dosimeter will permit calculation of the delivered irradiation dose and a dose/effect relation between the different parameters.
This multicentric cross-over study with a multidisciplinary approach will act for a direct benefit on testis function in patients aged 18-45 treated by 131iodine for thyroid cancer. Samples measurements timing will be: after surgery, 2 and 12 months after 131iodine administration. Therefore, endpoints such as medical examination, exocrine and endocrine testis function in blood and spem sampling will be assessed in order to obtain spermogram, Sperm Cytogram, aneuploidy/apoptosis, minisatellites region mutation rate. Medical examination will take place in each local site, either from endocrinology, oncology, nuclear medicine departments. The sperm samples and spermogram, Sperm Cytogram, irradiation- induced abnormalises studies will be centralized at the CECOS (Tenon Hospital, Paris, France). Hormonal dosages will be processed in Bicetre Hospital (Kremlin-Bicetre, France). Minisatellites mutations study processed on frozen sperm samples will take place in the Genetic of Radiosensibility Department (Commissionership in the energy atomic, SACLAY, France).
This study would permit to measure out the minisatellites region mutation rate frequency, aneuploidy and DNA damage frequency, and finally kinetics of those alterations after 131iodine irradiation for human thyroid cancer. At the clinical level, practitioners would more precisely advise their patients on potential fertility risks and help to choose the appropriate practice in order to preserve it before thyroid cancer treatment. Knowing those results, it may redefine iodine indication. The knowledge of irradiation-induced genomic abnormalises is critical, regarding the growing number of examinations (Computed Tomography or Positron Emission Tomography-scans), known to deliver the same amount of irradiation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75012
- Saint Antoine Hospital, Endocrinology Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men from 18 to 55 years treated by thyroid surgery for papillary carcinoma followed by iodine 131 radiotherapy
- informed consent
Exclusion Criteria:
- The patients under supervision (guardianship), under guardianship.
- Patients of less than 18 years old and furthermore of 55 years old
- Hypogonadism known or bare during the hormonal balance sheet of inclusion.
- The patients with a history of definitive azoospermia·
- Azoospermia at baseline spermogram
- Chemotherapy or radiotherapy history
- The patients exposed to toxic substance for the spermatogenesis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Patients treated by 131 iodine for thyroid cancer
|
100 mCi 131 iodine irradiation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A genomic instability within the germinal line
Time Frame: 12 months after iodine131 administration
|
To study a genomic instability within the germinal line, based on a significant mutation rate analysis in their minisatellite regions after 100 mCi 131 iodine irradiation compared to the baseline spermogram of each patient, thus being his own control case in a cross-over study
|
12 months after iodine131 administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The spermatozoid apoptosis and aneuploidy levels
Time Frame: 1 month before iodine131 administration
|
1 month before iodine131 administration
|
The exocrine and endocrine testicular function
Time Frame: 1 month before iodine131 administration
|
1 month before iodine131 administration
|
The radiation doses delivered to the testis in exposed patients
Time Frame: 72 hours after 131 iodine administration
|
72 hours after 131 iodine administration
|
The exocrine and endocrine testicular function
Time Frame: 3 months after iodine131 administration
|
3 months after iodine131 administration
|
The exocrine and endocrine testicular function
Time Frame: 12 months after iodine131 administration
|
12 months after iodine131 administration
|
The spermatozoid apoptosis and aneuploidy levels
Time Frame: 3 months after iodine131 administration
|
3 months after iodine131 administration
|
The spermatozoid apoptosis and aneuploidy levels
Time Frame: 12 months after iodine131 administration
|
12 months after iodine131 administration
|
Collaborators and Investigators
Investigators
- Principal Investigator: Philippe Bouchard, MD, PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Thyroid Diseases
- Head and Neck Neoplasms
- Neoplasms, Squamous Cell
- Thyroid Neoplasms
- Carcinoma, Papillary
- Physiological Effects of Drugs
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Trace Elements
- Micronutrients
- Iodine
Other Study ID Numbers
- P040419
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Neoplasms
-
Kahramanmaras Sutcu Imam UniversityCompletedThyroid Diseases | Thyroid Cancer | Thyroid Nodule | Thyroid Neoplasms Benign
-
Aarhus University HospitalOdense University Hospital; University of AarhusEnrolling by invitationThyroid Cancer | Thyroid Nodule (Diagnosis)Denmark
-
Maria Sklodowska-Curie National Research Institute...CompletedThyroid Cancer | Thyroid Nodule | Thyroid NeoplasmPoland
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); University of MichiganCompletedThyroid Cancer | Thyroid Nodule | Benign Thyroid NoduleUnited States
-
Wuhan UniversityRecruitingThyroid Carcinoma | Thyroid Nodule (Benign) | Ablation; RetinaChina
-
Norman EberhardtCompletedThyroid Carcinoma | Thyroid Cancer | Thyroid Adenoma | Cancer of the Thyroid | Neoplasms, ThyroidUnited States
-
Rigen BiotechRenJi Hospital; Tianjin Medical University Cancer Institute and Hospital; Guangdong... and other collaboratorsRecruitingThyroid Cancer | Thyroid NoduleChina
-
University of FloridaNational Cancer Institute (NCI)RecruitingThyroid Cancer | Thyroid NodulesUnited States
-
Inha University HospitalRecruitingThyroid Cancer | Thyroid NoduleKorea, Republic of
-
Shanghai 10th People's HospitalUnknown
Clinical Trials on Administration of 131 iodine
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditionsUnited States
-
John MarisAvailableNeuroblastoma | Childhood Metastatic PheochromocytomaUnited States
-
University of NebraskaNational Cancer Institute (NCI); Coulter Pharmaceutical, Inc.Terminated
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterGustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid... and other conditionsUnited States
-
Sun Yat-sen UniversityUnknownHypothyroidism | ExophthalmosChina
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
University of PisaCompletedThyroid Diseases